Pfizer Weighing Options In Medical Technology Group Divestment
This article was originally published in The Gray Sheet
Executive Summary
Schneider's rapid-exchange balloon catheter patent portfolio will be a key draw for firms considering whether to acquire the Pfizer unit, which has annual sales of $330 mil. On Feb. 26, the drug maker announced that it is "exploring strategic options" for divesting its $1.45 bil. medical technology group (MTG), which, in addition to Schneider, includes Howmedica ($880 mil.) and American Medical Systems ($90 mil.).
You may also be interested in...
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.